scholarly journals Health Utility Scores for People With Type 2 Diabetes in U.S. Managed Care Health Plans: Results from Translating Research Into Action for Diabetes (TRIAD)

Diabetes Care ◽  
2012 ◽  
Vol 35 (11) ◽  
pp. 2250-2256 ◽  
Author(s):  
P. Zhang ◽  
M. B. Brown ◽  
D. Bilik ◽  
R. T. Ackermann ◽  
R. Li ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Managed Care ◽  
Health Utility ◽  
Health Plans ◽  
Care Health ◽  
Utility Scores

Within trial cost-effectiveness of a structured lifestyle intervention in adults with overweight/obesity and type 2 diabetes: Results from the Action for Health in Diabetes (Look AHEAD) Study

2020 ◽  
Author(s):  
Ping Zhang ◽  
Karen M. Atkinson ◽  
George Bray ◽  
Haiying Chen ◽  
Jeanne M. Clark ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
Lifestyle Intervention ◽  
Health Utility Index ◽  
Health Benefit ◽  
Cost Effective ◽  
Health Utility ◽  
Health Care Expenditures ◽  
Quality Adjusted Life Year

<b>OBJECTIVE </b>To assess the cost-effectiveness (CE) of an intensive lifestyle intervention (ILI) compared to standard diabetes support and education (DSE) in adults with overweight/obesity and type 2 diabetes, as implemented in the Action for Health in Diabetes study. <p><b>RESEARCH DESIGN AND METHODS</b> Data were from 4,827 participants during the first 9 years of the study from 2001 to 2012. Information on Health Utility Index-2 and -3, SF-6D, and Feeling Thermometer [FT]), cost of delivering the interventions, and health expenditures were collected during the study. CE was measured by incremental cost-effectiveness ratios (ICERs) in costs per quality-adjusted life year (QALY). Future costs and QALYs were discounted at 3% annually. Costs were in 2012 US dollars. </p> <p><b>RESULTS </b><a>Over the </a>9 years studied, the mean cumulative intervention costs and mean cumulative health care expenditures were $11,275 and $64,453 per person for ILI and $887 and $68,174 for DSE. Thus, ILI cost $6,666 more per person than DSE. Additional QALYs gained by ILI were not statistically significant measured by the HUIs and were 0.17 and 0.16, respectively, measured by SF-6D and FT. The ICERs ranged from no health benefit with a higher cost based on HUIs, to $96,458/QALY and $43,169/QALY, respectively, based on SF-6D and FT. </p> <p><b>Conclusions </b>Whether<b> </b>ILI was cost-effective over the 9-year period is unclear because different health utility measures led to different conclusions. </p>

scholarly journals Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective

2018 ◽  
Vol Volume 10 ◽  
pp. 791-803 ◽  
Author(s):  
Dhvani Shah ◽  
Nancy A Risebrough ◽  
Johnna Perdrizet ◽  
Neeraj N Iyer ◽  
Cory Gamble ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Cost Effectiveness ◽  
Managed Care ◽  
Budget Impact ◽  
Diabetes Patients

scholarly journals Patient Health Utility Equations for a Type 2 Diabetes Model

Diabetes Care ◽  
2020 ◽  
pp. dc201207
Author(s):  
Simon J. Neuwahl ◽  
Ping Zhang ◽  
Haiying Chen ◽  
Hui Shao ◽  
Michael Laxy ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Health Utility ◽  
Diabetes Model ◽  
Patient Health
Sign in / Sign up

Export Citation Format

Share Document